Search

Displaying results 3501 - 3510 of 10000 in total
  1. Target

    NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7

    go.drugbank.com/bio_entities/BE0000512
    TargetHumans

    Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. … Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

    Synonyms: Complex I-B18
  2. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [L43987] Compared to the current standard of therapy for migraine treatment, namely triptans such as [sumatriptan] and [almotriptan], CGRP antagonists present several advantages. … Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults.

  3. Drug

    Tirbanibulin

    go.drugbank.com/drugs/DB06137
    ApprovedInvestigational

    It is marketed under the brand name Klisyri. … Tirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin.

  4. Drug

    Alofanib

    go.drugbank.com/drugs/DB20918
    Investigational

    Alofanib is a small molecule drug. The usage of the INN stem '-anib' in the name indicates that Alofanib is a angiogenesis inhibitor. … Alofanib is under investigation in clinical trial NCT04071184 (Study of Alofanib in Patients With Metastatic Gastric Cancer). Alofanib has a monoisotopic molecular weight of 413.07 Da.

  5. Drug

    Utatrectinib

    go.drugbank.com/drugs/DB21295
    Investigational

    Utatrectinib is a small molecule drug. The usage of the INN stem '-trectinib' in the name indicates that Utatrectinib is a tropomyosin receptor kinase (TRK) inhibitor. … Utatrectinib is under investigation in clinical trial NCT01468324 (AZD7451 for Recurrent Gliomas). Utatrectinib has a monoisotopic molecular weight of 382.17 Da.

  6. Drug

    Donanemab

    go.drugbank.com/drugs/DB16647
    ApprovedInvestigational

    Donanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta (Aβ), [L50978] which is found in the brain amyloid plaques that

  7. Drug

    Apadamtase alfa

    go.drugbank.com/drugs/DB15164
    ApprovedInvestigational

    [A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP. … Thrombotic thrombocytopenic purpura (TTP) is a rare blood clotting disorder characterized by thrombocytopenia, microangiopathic hemolytic anemia, and various degrees of organ damage.

  8. Drug

    Nebivolol

    go.drugbank.com/drugs/DB04861
    ApprovedInvestigational

    Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. … [A182579] Nebivolol and other beta blockers are generally not first line therapies as many patients are first treated with thiazide diuretics.

  9. Drug

    Olmesartan

    go.drugbank.com/drugs/DB00275
    ApprovedInvestigational

    [A185906,A185909,A185912] Orally available olmesartan is produced as the prodrug olmesartan medoxomil which is rapidly converted _in vivo_ to the pharmacologically active olmesartan. … Olmesartan is commonly used for the management of hypertension and Type 2 Diabetes-associated nephropathy, particularly in patients who are unable to tolerate ACE inhibitors.

  10. Drug

    Artenimol

    go.drugbank.com/drugs/DB11638
    ApprovedInvestigational

    Artemisinin combination therapy is highly effective against malaria and stongly recommended by the World Health Organization [L1156]. … Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated *Plasmodium falciparum* infections [FDA Label].